News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nektar Therapeutics (NKTR): A Sweet Or Sour Investment?



6/15/2017 6:27:24 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
After a decade plus of failed investment in the inhaled insulin, Exubera, Pfizer Inc. (NYSE:PFE) cut the losses via terminating its partnership with Nektar Therapeutics (NASDAQ:NKTR) on Oct. 18, 2007. Next year, Nektar gave up the hope for inhaled insulin by terminating all negotiations (with potential marketing partners) for the "the bong."

Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES